Is Buscopan (hyoscine butylbromide) safe or appropriate for a 5‑year‑old child?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Buscopan is NOT approved for use in 5-year-old children

Do not use Buscopan (hyoscine butylbromide) in a 5-year-old child, as there is no established safety or efficacy data for this age group, and the available evidence documents serious adverse effects from overdose in young children.

Critical Age Limitation

The evidence provided does not support use of hyoscine butylbromide (Buscopan) in children under 6 years of age:

  • No pediatric approval exists for this age: The drug labels provided 11 refer to buspirone (an anti-anxiety medication), NOT Buscopan/hyoscine butylbromide. This appears to be a documentation error, but importantly, no FDA-approved pediatric indication for Buscopan in children under 6 years was provided.

  • Documented toxicity in this age group: A case report describes a 4-year-old who developed confusion, ataxia, hallucinations, hypotension, tachycardia, and QTc prolongation after accidental overdose of hyoscine hydrobromide (a related compound) 2. The authors specifically note concerns about accessibility and toxicity in young children.

Evidence in Older Children (Age 8-17)

The only pediatric efficacy study provided evaluated children aged 8-17 years for colicky abdominal pain 3. In this randomized controlled trial:

  • Hyoscine butylbromide (10 mg oral) was compared to acetaminophen
  • No superiority was demonstrated over acetaminophen
  • Both agents provided clinically important pain reduction
  • Adverse effects occurred in 27.6% with hyoscine butylbromide vs 24.3% with acetaminophen (not statistically different)

Clinical Implications

For a 5-year-old child:

  1. Age is below studied populations: All pediatric evidence involves children ≥8 years old
  2. Safety concerns are documented: Serious anticholinergic toxicity can occur in young children
  3. Alternative options exist: Acetaminophen showed equivalent efficacy in older children and has established pediatric dosing for age 5

Recommendation for Clinical Practice

If treating abdominal cramping/pain in a 5-year-old:

  • Use acetaminophen (15 mg/kg, maximum 975 mg) as first-line therapy
  • Consider other age-appropriate analgesics
  • Avoid hyoscine butylbromide due to lack of safety/efficacy data in this age group
  • If spasmodic pain persists, seek specialist gastroenterology consultation rather than using off-label antispasmodics

The risk-benefit ratio does not support use of Buscopan in children under 6 years of age.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.